The domestic epidemic has been raging recently, and most hospitals in the country are operating at high capacity. Taking Beijing Chaoyang Hospital as an example, it used to receive more than 100 cases a day, but now it receives or surges to about 500 patients a day. Among them, the elderly and critically ill patients with underlying diseases are mainly in serious condition. In addition, there is a lot of controversy about what drugs should be used to treat COVID-19, especially about the efficacy of LHQW. Pfizer Is Paxlovid reliable? Is it a way for imperialism to cut leeks?
Recently, there have been frequent good news in the domestic pharmaceutical field. In addition to the approved Azvudine (an HIV reverse transcriptase (RT) inhibitor), the anti-COVID-19 drug SIM0417 (3CL protease inhibitor) developed by Simcere Pharmaceuticals has just completed the enrollment of patients in the Phase III clinical trial.
On December 29, 2022, the international authoritative medical journal "New England Medical Journal" published online the phase III head-to-head comparison data between Junshi Biological anti-new coronavirus oral drug VV116 (a small molecule drug inhibitor targeting new coronavirus virus RdRp) and Pfizer Paxlovid, showing non-inferior effects.
This clinical trial is hosted by Professor Zhao Ren of Shanghai Ruijin Hospital, Professor Gaoyuan of Shanghai Renji Hospital, and Academician Ningguang of Shanghai Ruijin Hospital. ,
In the end, the VV116 and Paxlovid groups recruited 384 and 387 patients respectively, of which 23.4% were unvaccinated and 92.1% were mild.
The results of the primary endpoint (clinical symptom recovery time) showed that the median symptom recovery time was 4 days in the VV116 group and 5 days in the Paxlovid group (hazard ratio, 1.17; 95% confidence interval, 1.02~1.36).
In terms of safety, VV116 also shows a similar good safety profile to Paxlovid, and is even lower than Paxlovid in the incidence of some adverse reactions, such as dysgeusia.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-